Detection and significance of minority quasispecies of drug-resistant HIV-1

Journal of HIV Therapy

Volumn 11, Issue 4, 2006, Pages 74-81

  Metzner, Karin J ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; DIAGNOSTIC TEST; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; MOLECULAR CLONING; MULTIDRUG RESISTANCE; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SINGLE DRUG DOSE; TREATMENT FAILURE; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIREMIA; VIRUS DETECTION; VIRUS LOAD; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; TREATMENT OUTCOME;

EID: 33846618828     PISSN: 14620308     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Egger M, Hirschel B, Francioli P et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ, 1997, 315, 1194-1199.
2. Sterne JA, Hernan MA, Ledergerber B et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet, 2005, 366, 378-384.
3. Phillips AN, Dunn D, Sabin C et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS, 2005, 19, 487-494.
4. Korn K, Reil H, Walter H et al. Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results. J Clin Microbiol, 2003, 41, 3559-3565.
5. Schuurman R, Brambilla D, de Groot T et al. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 Genotyping Proficiency Program. AIDS Res Hum Retroviruses, 2002, 18, 243-248.
6. Ho DD, Neumann AU, Perelson AS et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 1995, 373, 123-126.
7. Wei X, Ghosh SK, Taylor ME et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature, 1995, 373, 117-122.
8. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science, 1995, 267, 483-489.
9. Wong JK, Hezareh M, Gunthard HF et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science, 1997, 278, 1291-1295.
10. Davey RT, Jr, Bhat N, Yoder C et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A, 1999, 96, 15109-15114.
11. Garcia F, Plana M, Vidal C et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS, 1999, 13, F79-F86.
12. Harrigan PR, Whaley M and Montaner JS. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS, 1999, 13, F59-F62.
13. Neumann AU, Tubiana R, Calvez V et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS, 1999, 13, 677-683.
14. Wolinsky SM, Wike CM, Korber BT et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science, 1992, 255, 1134-1137.
15. Zhu T, Mo H, Wang N et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science, 1993, 261, 1179-1181.
16. Zhang LQ, MacKenzie P, Cleland A et al. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol, 1993, 67, 3345-3356.
17. Wolfs TF, Zwart G, Bakker M et al. HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology, 1992, 189, 103-110.
18. Learn GH, Muthui D, Brodie SJ et al. Virus population homogenization following acute human immunodeficiency virus type 1 infection. J Virol, 2002, 76, 11953-11959.
19. Long EM, Martin HL Jr, Kreiss JK et al. Gender differences in HIV-1 diversity at time of infection. Nat Med, 2000, 6, 71-75.
20. Ritola K, Pilcher CD, Fiscus SA et al. Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol, 2004, 78, 11208-11218.
21. Chun TW, Carruth L, Finzi D et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature, 1997, 387, 183-188.
22. Pariente N, Pernas M, de la Rosa R et al. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes. J Med Virol, 2004, 73, 350-361.
23. Martinez-Picado J, DePasquale MP, Kartsonis N et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci U S A, 2000, 97, 10948-10953.
24. Furtado MR, Callaway DS, Phair JP et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med, 1999, 340, 1614-1622.
25. Shehu-Xhilaga M, Tachedjian G, Crowe SM et al. Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1. Curr Mol Med, 2005, 12, 1705-1719.
26. Miller V, Sabin C, Hertogs K et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS, 2000, 14, 2857-2867.
27. Izopet J, Massip P, Souyris C et al. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS, 2000, 14, 2247-2255.
28. Lukashov VV, Huismans R, Jebbink MF et al. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs. AIDS Res Hum Retroviruses, 2001, 17, 807-818.
29. Delaguerre C, Valantin MA, Mouroux M et al. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS, 2001, 15, 2189-2191.
30. Albrecht D, Zollner B, Feucht HH et al. Reappearance of HIV multidrug-resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy. J Clin Virol, 2002, 24, 93-98.
31. Deeks SG, Grant RM, Wrin T et al. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS, 2003, 17, 361-370.
32. Halvas EK, Aldrovandi GM, Balfe P et al. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol, 2006, 44, 2612-2614.
33. Metzner KJ, Rauch P, Walter H et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS, 2005, 19, 1819-1825.
34. Flys T, Nissley DV, Claasen CW et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis, 2005, 192, 24-29.
35. Johnson JA, Li JF, Morris L et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis, 2005, 192, 16-23.
36. Loubser S, Balfe P, Sherman G et al. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS, 2006, 20, 995-1002.
37. Palmer S, Boltz V, Martinson N et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A, 2006, 103, 7094-7099.
38. Flys T, Mwatha A, Donnell D et al. Fading of K103N-containing HIV-1 variants after initial and repeated exposure to single dose nevirapine for prevention of HIV-1 mother-to-child transmission (HIVNET 012). Antivir Ther, 2006, 11, S53 (abstract 45).
39. Birk M, Svedhem V, and Sonnerborg A. Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. AIDS, 2001, 15, 1359-1368.
40. Deeks SG, Wrin T, Liegler T et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med, 2001, 344, 472-480.
41. Walter H, Low P, Harrer T et al. No evidence for persistence of multidrug-resistant viral strains after a 7-month treatment interruption in an HIV-1-infected individual. J Acquir Immune Defic Syndr, 2002, 31, 137-146.
42. Hance AJ, Lemiale V, Izopet J et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol, 2001, 75, 6410-6417.
43. Palmer S, Boltz V, Maldarelli F et al. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS, 2006, 20, 701-710.
44. Lecossier D, Shulman NS, Morand-Joubert L et al. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr, 2005, 38, 37-42.
45. Kapoor A, Jones M, Shafer RW et al. Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay. J Virol, 2004, 78, 7112-7123.
46. Roquebert B, Malet I, Wirden M et al. Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors. AIDS, 2006, 20, 287-289.
47. Svarovskaia ES, Margot NA, Bae AS et al. Allele-specific PCR shows low-level K65R in treatment-experienced patients with L74V in the absence of TAMs. Antivir Ther, 2006, 11, S80 (Abstr. 70).
48. Johnson JA, Li JF, Wei X et al. Baseline detection of low-frequency drug resistance-associated mutations is strongly associated with virological failure in previously antiretroviral-naive HIV-1-infected persons. Antivir Ther, 2006, 11, S79 (Abstr. 69).
49. Lehrman G, Hogue IB, Palmer S et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet, 2005, 366, 549-555.
50. Schuurman R, Demeter L, Reichelderfer P et al. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol, 1999, 37, 2291-2296.
51. Larder BA, Kellam P, and Kemp SD. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS, 1991, 5, 137-144.
52. Eastman PS, Urdea M, Besemer D et al. Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations. J Acquir Immune Defic Syndr Hum Retrovirol, 1995, 9, 264-273.
53. Schmit JC, Ruiz L, Stuyver L et al. Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. J Virol Methods, 1998, 73, 77-82.
54. Metzner KJ, Bonhoeffer S, Fischer M et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis, 2003, 188, 1433-1443.
55. Bergroth T, Sonnerborg A, and Yun Z. Discrimination of lamivudine resistant minor HIV-1 variants by selective real-time PCR. J Virol Methods, 2005, 127, 100-107.
56. Moser MJ, Ruckstuhl M, Larsen CA et al. Quantifying mixed populations of drug-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother, 2005, 49, 3334-3340.
57. Descamps D, Ait-Khaled M, Craig C et al. Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/lamivudine-containing HAART regimen. Antivir Ther, 2006, 11, 701-705.
58. Mohey R, Tolstrup M, Jorgensen LB et al. HIV-1 Reverse Transcriptase Gene 103K/N and 184M/V combinations in tandem: detection and quantification of HIV-1 Populations in the CD45RO+ T-cell compartment by a double-ARMS real-time PCR assay. J Acquir Immune Defic Syndr, 2006, 41, 160-167.
59. Resch W, Parkin N, Stuelke EL et al. A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics. Proc Natl Acad Sci U S A, 2001, 98, 176-181.
60. Stuyver L, Wyseur A, Rombout A et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother, 1997, 41, 284-291.
61. Halfon P, Durant J, Clevenbergh P et al. Kinetics of disappearance of resistance mutations and reappearance of wild-type during structured treatment interruptions. AIDS, 2003, 17, 1351-1361.
62. Garcia-Bujalance S, de Guevara CL, Gonzalez-Garcia J et al. Comparison between sequence analysis and a line probe assay for testing genotypic resistance of human immunodeficiency virus type 1 to antiretroviral drugs. J Clin Microbiol, 2005, 43, 4186-4188.
63. Barnas D, Kearney M, Boltz V et al. Multi-genome sequencing (MGS): a new, sensitive method of detecting low frequency drug-resistant mutants. Antivir Ther, 2006, 11, S189 (Abstr. 169).
64. Edelstein RE, Nickerson DA, Tobe VO et al. Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J Clin Microbiol, 1998, 36, 569-572.
65. Villahermosa ML, Beck I, Perez-Alvarez L et al. Detection and quantification of multiple drug resistance mutations in HIV-1 reverse transcriptase by an oligonucleotide ligation assay. J Hum Virol, 2001, 4, 238-248.
66. Beck IA, Mahalanabis M, Pepper G et al. Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. J Clin Microbiol, 2002, 40, 1413-1419.
67. Haddad DN, Birch C, Middleton T et al. Evidence for late stage compartmentalization of HIV-1 resistance mutations between lymph node and peripheral blood mononuclear cells. AIDS, 2000, 14, 2273-2281.
68. Palmer S, Kearney M, Maldarelli F et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol, 2005, 43, 406-413.
69. Nissley DV, Halvas EK, Hoppman NL et al. Sensitive phenotypic detection of minor drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants. J Clin Microbiol, 2005, 43, 5696-5704.
70. Tsibris A, Russ C, Lee W et al. Detection and quantification of minority HIV-1 env V3 loop sequences by ultra-deep sequencing: preliminary results. Antivir Ther, 2006, 11, S74 (Abstr. 66).
71. Dykes C, Najjar J, Bosch RJ et al. Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. J Infect Dis, 2004, 189, 1091-1096.
72. Bae AS, Waters JM, Margot NA et al. Pre-existing L74V is a risk factor for virological non-response and development of K65R in patients taking tenofovir df (TDF). Antivir Ther, 2004, 9, S174 (Abstr. 158).
73. Rouse E, Gerondelis P, Paulsen D et al. Clonal analysis of week 12 virologic non-responders receiving tenofovir/abacavir/lamivudine in ESS30009. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005, Abstr. 720.
74. Moffatt A, Gerondelis P, Stone C et al. Population and clonal sequence analyses before and after selection of reverse transcriptase mutation L74V in HIV-1 positive subjects treated with abacavir (ABC)/lamivudine (3TC)/efavirenz (EFV). 10th European AIDS (EACS) Conference, Dublin, November 2005, Abstr. PE 3/2.
75. Frankel F, Brenner BG, Moisi D et al. Diminished representation of HIV-1 variants harbouring M184V mutations in primary HIV infection (PHI). Antivir Ther, 2006, 11, S51 (Abstr. 43).